Digbei.com reported on July 31 that the Beijing Stock Exchange-listed company Ternary Gene (837344. On July 11 and July 26, BJ) successively received visits and surveys from securities firms and investment institutions, including China Asset Management, Shenwan Hongyuan Securities, Galaxy Securities, CICC, Guotai Junan, etc.
Ternary Gene is mainly engaged in the research, production and marketing of human interferon α1b (trade name: Yundesu ®), adheres to original technology and market innovation, and its products have occupied a leading position in the market share of interferon in mainland China for many years, and have significant advantages in the treatment of a variety of pediatric viral infections. The company's products include a variety of dosage forms, especially water injection dosage form products, which are developed by the company in combination with unique molecular characteristics, with high process difficulty, clinical convenience, safety and stability characteristics, easy to promote and use, and are listed as national key new products.
Based on the advantages of technology and products, in recent years, with the implementation of the three-medical linkage reform and the policy of centralized drug procurement, the company's Yundesu products have successively won the bid for centralized procurement, which promotes hospital access and is conducive to further expanding market share.
In addition, the new drugs under development of ternary genes have also attracted institutional attention. According to reports, after the completion of the phase III clinical trial, the company's human interferon α1b nebulized inhalation treatment project for pediatric RSV pneumonia has completed the collation of all registration materials, and communicated with the Center for Drug Evaluation (CDE) of the National Medical Products Administration, and will promote the project application work in accordance with the procedures in the future. The field of treatment of respiratory tract infections in children targeted by this product is still a blank market, and the future market potential is promising.
Successively won the bid for centralized procurement to further expand its market share
The reform of the "three-medicine linkage" of medical, pharmaceutical and medical insurance in mainland China is progressing in an orderly manner, and interferon drugs with a wide range of biological activities and immunomodulatory functions will usher in a broader market space and application scenarios. In particular, with the release of the 2023 version of the National Medical Insurance Catalogue, all the indications listed in the product insert of the ternary gene product human interferon α1b (injection) are included in the reimbursable category, and the application of the company's products in medical institutions at all levels will be further expanded.
With the implementation of the three-medical linkage reform and the centralized drug procurement policy, the company's Yundesu products have increased the access scope of hospitals at all levels, especially large hospitals, and expanded the number of hospitals where drugs are admitted to hospitals in the centralized procurement area.
Taking the "Guangdong Alliance Diclofenac and Other Drugs Centralized Procurement" as an example, the company's main product, human interferon α1b (powder injection) for injection, three specifications have been comprehensively and quickly admitted to the hospital, and the centralized procurement will be implemented from January 10, 2023. In 2023, the company added 460 new medical terminals in Guangdong, Henan, Shanxi and other provinces, rapidly expanding the coverage of medical terminals.
In March this year, the ternary gene Yundesu ® once again won the bid for the centralized procurement of interferon interpolon led by the Jiangxi Provincial Medical Insurance Bureau. The company's human interferon α1b injection (water injection) 5 specifications, recombinant human interferon α1b spray, human interferon α1b eye drops were selected, the agreed procurement period is 4 years, including 24 provincial procurement entities, from May to August this year, the provinces have begun to implement, at present, about 20 provinces have issued official notices.
Winning bids for centralized procurement will increase the number of hospital access to the company as a whole. In the short term, the cost of hospital access for the company's products will be reduced, the efficiency of hospital access will be improved, and centralized procurement will promote hospital access. In the long run, it is conducive to the further rapid spread of the product to a broader market, the spread of the product to more level hospitals, the improvement of the accessibility and utilization rate of Yundesu ® in clinical treatment, and the further expansion of market share.
The new drugs under development fill the gap, and the market potential is large
Among the new drug projects under development by ternary genes, the fastest progress is the human interferon α1b aerosol inhalation project for the treatment of pediatric RSV pneumonia. The prospect and marketing progress of the new drug have attracted the attention of institutions.
From the perspective of application fields, the treatment of respiratory syncytial virus (RSV) infection has been a challenge in the global medical field. There is an urgent need for new drugs in the therapeutic field of RSV infection to provide patients with safer, more effective, less expensive, and more accessible treatment options.
In terms of the current market structure, there is still a gap in the field of treating children's respiratory tract infections, and the development of new drug products of ternary gene is in a leading position in terms of time schedule.
The R&D project of ternary human interferon α1b nebulized inhalation for the treatment of pediatric RSV pneumonia has achieved good results, and the phase III clinical trial has been completed, reaching the primary endpoint. According to the company's internal phase III clinical trial summary report and previous evidence-based medical research, human interferon α1b nebulized inhalation has the advantages of strong targeting, good safety, easy operation and high compliance in the treatment of RSV pneumonia in children.
In terms of listing progress, the company has completed the collation of all registration materials, communicated with the Center for Drug Evaluation (CDE) of the National Medical Products Administration, and will promote the project application in accordance with the procedures in the future. In addition, the company's professional business promotion team provides a solid guarantee for the products to quickly enter the market.
According to the relevant market forecast report, the market space for pediatric virus infection is huge and on the rise. After the new drug is launched, Ternary Gene will not only meet the urgent market demand for RSV treatment drugs in children, but also gradually bring good news to children and their families in the treatment of other respiratory viral infections, and has huge market potential.
In addition to consolidating the pediatric respiratory viral disease segment, the company is actively entering new markets, such as adult respiratory viral diseases, gynecologic viral diseases, skin viral diseases, cancer treatment, etc. According to the relevant market forecast report, the hepatitis B treatment market has a low penetration rate of interferon, and the potential treatment population and market space are huge. The market space of human interferon α1b in melanoma is expected to show an upward trend in the next decade. In addition, the company's products are also expected to continue to expand their application space in the market of dermatological drugs, ophthalmic anti-infective drugs, gynecological anti-infective drugs and other drugs.
In addition, the company has settled in the new factory this year, and the production capacity has ushered in a qualitative improvement, which is also conducive to expanding the market scale and strengthening new products. According to reports, the company's new plant has designed and built a number of preparation production lines, covering powder injection, water injection, spray, eye drops, pre-filled injections and blow-fill-seal integrated atomization inhalers and other dosage forms, providing sufficient production capacity guarantee for existing products and upcoming new products.
(Ternary Gene New Factory)